Risk of liver decompensation among HIV/Hepatitis C virus-coinfected individuals with advanced fibrosis: Implications for the timing of therapy

Clinical Infectious Diseases

Volumn 57, Issue 10, 2013, Pages 1401-1408

  Macías, Juan ^a   Márquez, Manuel ^b   Téllez, Francisco ^c   Merino, Dolores ^d   Jiménez Aguilar, Patricia ^e   López Cortés, Luis F ^f   Ortega, Enrique ^g   Von Wichmann, Miguel A ^h   Rivero, Antonio ⁱ   Mancebo, María ^a   Santos, Jesús ^b   Pérez Pérez, Montserrat ^c   Suárez Lozano, Ignacio ^d   Romero Palacios, Alberto ^e   Torres Cornejo, Almudena ^f   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c Hospital de la Linea de la Concepcion   (Spain)

^d Infectious Diseases Unit   (Spain)

^e HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^f Instituto de Biomedicina de Sevilla   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Chronic hepatitis C; Liver biopsy; Liver decompensations; Liver fibrosis; Liver stiffness

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROBABILITY; THROMBOCYTE COUNT;

CHRONIC HEPATITIS C; LIVER BIOPSY; LIVER DECOMPENSATIONS; LIVER FIBROSIS; LIVER STIFFNESS;

ADULT; ANALYSIS OF VARIANCE; BIOPSY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84887952863     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit537     Document Type: Article

References (27)

1. Pineda JA, García-García JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-30.
2. Macías J., Berenguer J, Japón MA, et al Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-63.
3. Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related endstage liver disease. AIDS 2006; 20: 49-57.
4. Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56: 1646-53.
5. Pineda JA, Caruz A, Rivero A. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51: 788-95.
6. Poordad F, McCone J, Bacon B.R., et al Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-416.
8. Sulkowski MS, Sherman KE, Soriano V, et al Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. In: Program and abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 9-13 November 2012. Abstract 54.
9. Sulkowski M, Pol S, Cooper C., et al Boceprevir plus pegylated interferon/ribavirin for the treatment of HCV/HIV coinfected patients. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 5-8 March 2011. Abstract 47.
10. Ingiliz P, Rockstroh J. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012; 32: 1194-9.
11. Sulkowski M. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013; 207(SUPPL. 1): S26-32.
12. Berenguer J, Calleja JL, Esteban R, et al Criterios y recomendaciones generales para el tratamiento con boceprevir y telaprevir de la hepatitis crónica C en pacientes infectados por el VIH, el pacientes trasplantados y en población pediátrica. Agencia Española de Medicamentos y Productos Sanitarios [in Spanish]. Ministerios de Sanidad, Servicios Sociales e Igualdad, 26 July 2012. Available at: http://www.aemps.gob.es/ medicamentosUsoHumano/medSituacionesEspeciales/docs/criterios-VHC-off-label.pdf. Accessed 13 April 2013.
13. Hezode C, Dorival C, Zoulim F., et al Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 9-12 November 2012.
14. Martel-Laferriere V., Brinkley S, Bichoupan K., et al On-treatment responses to telaprevir-based hepatitis C treatment are similar in HIV/hepatitis C virus co-infected and hepatitis C virus mono-infected patients. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2-6 March 2013. Abstract 679.
15. Kostman J, Gilmore J, Binkley A., et al Risk of anemia in HIV/hepatitis C virus co-infected patients treated with telaprevir-based hepatitis C virus therapy. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2-6 March 2013. Abstract 677.
16. Benito JM, Bichoupan K, Soriano V., et al Triple combination therapy for hepatitis C with telaprevir exhibits higher early antiviral potency than with boceprevir regardless HIV status. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2-6 March 2013. Abstract 676.
17. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
18. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.
19. Vergara S, Macías J, Rivero A., et al The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-74.
20. Merchante N, Rivero-Juárez A, Téllez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56: 228-38.
21. Pineda JA, Aguilar-Guisado M, Rivero A., et al Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49: 1274-82.
22. Morgan TR, Ghany MG, Kim H.Y., et al Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
23. Limketkai BN, Mehta SH, Sutcliffe C.G., et al Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-8.
24. Berenguer J, Alvarez-Pellicer J, Martín PM, et al Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
25. Berenguer J, Alvarez-Pellicer J, Carrero A., et al Clinical effects of viral relapse after interferon plus ribavirin in patients coinfected with human immunodeficiency virus and hepatitis C virus. J Hepatol 2013; 58: 1104-1112.
26. Bacon BR, Gordon SC, Lawitz E, et al Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
27. Zeuzem S, Andreone P, Pol S., et al Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.